Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia.
Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia.
Ann Thorac Surg. 2018 Jul;106(1):46-51. doi: 10.1016/j.athoracsur.2018.01.085. Epub 2018 Mar 8.
As a marker of myocardial injury, troponin level correlates with adverse outcomes after myocardial infarction (MI). We hypothesized that patients with a higher preoperative troponin level would have increased morbidity and mortality after coronary artery bypass grafting (CABG).
Preoperative troponin measurements were available for 1,272 patients who underwent urgent or emergent isolated CABG at our institution from 2002 to 2016. Logistic regression assessed the risk-adjusted effect of peak troponin level on morbidity and mortality. Long-term survival analysis was performed with Kaplan-Meier and Cox proportional hazards models.
Preoperative troponin was positive in 835 patients (65.6%). The median peak troponin for this group was 3.2 ng/mL (interquartile range, 0.6 to 11.9 ng/mL), with a median time from peak troponin to the operation of 3 days (interquartile range, 1 to 4 days). Positive troponin was associated with more significant comorbid conditions and more extensive coronary artery disease. Operative mortality (3.7% versus 1.1%, p = 0.009), major morbidity (11.7% versus 3.9%, p < 0.001), and long-term mortality (median survival 12.5 years versus 13.6 years, p = 0.01) were increased in the positive troponin group. After risk adjustment, positive troponin was not independently associated with increased operative mortality (odds ratio, 2.61; p = 0.053). Adjusted and unadjusted analysis showed the peak preoperative troponin level did not independently predict death at any time point (all odds ratios, 1.0; p > 0.05).
A positive preoperative troponin correlates with worse outcomes after CABG, but risk adjustment eliminates much of the short-term predictive value of this biomarker. Peak troponin level does not influence outcomes after CABG and is a poor predictor of events when The Society of Thoracic Surgeons predictive models are used.
肌钙蛋白作为心肌损伤的标志物,与心肌梗死(MI)后的不良预后相关。我们假设术前肌钙蛋白水平较高的患者在接受冠状动脉旁路移植术(CABG)后发病率和死亡率会增加。
我们对 2002 年至 2016 年在我院接受紧急或急诊单纯 CABG 的 1272 例患者的术前肌钙蛋白检测结果进行了回顾性分析。采用 logistic 回归评估了肌钙蛋白峰值对发病率和死亡率的风险调整作用。采用 Kaplan-Meier 和 Cox 比例风险模型进行长期生存分析。
术前肌钙蛋白阳性患者 835 例(65.6%)。该组的肌钙蛋白峰值中位数为 3.2ng/ml(四分位距,0.6-11.9ng/ml),肌钙蛋白峰值至手术的中位时间为 3 天(四分位距,1-4 天)。肌钙蛋白阳性与更严重的合并症和更广泛的冠状动脉疾病相关。肌钙蛋白阳性组的手术死亡率(3.7%比 1.1%,p=0.009)、主要发病率(11.7%比 3.9%,p<0.001)和长期死亡率(中位生存时间 12.5 年比 13.6 年,p=0.01)均增加。经风险调整后,肌钙蛋白阳性与手术死亡率增加无关(比值比,2.61;p=0.053)。调整和未调整分析均显示,术前肌钙蛋白峰值水平不能独立预测任何时间点的死亡(所有比值比,1.0;p>0.05)。
术前肌钙蛋白阳性与 CABG 后预后不良相关,但风险调整消除了该生物标志物的大部分短期预测价值。在使用胸外科医师协会预测模型时,肌钙蛋白峰值水平并不影响 CABG 后的结果,并且是事件的不良预测指标。